" class="no-js "lang="en-US"> Channa Debruyne - Medtech Alert
Monday, October 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Channa Debruyne

Channa Debruyne

About Channa Debruyne

Experienced Medical Director with a demonstrated history of working in the academic, regulatory and Pharma industry involved in all clinical aspects on drug development. Skilled in Oncology, Good Clinical Practice (GCP), Biotechnology, Drug Development, and Pharmaceutical Industry.

Related Story

Clinical Trials

 PDC*line Pharma Opens Last Cohort of PDC-LUNG-101 Clinical Trial | Pharmtech Focus

PDC*line Pharma Opens Last Cohort of PDC-LUNG-101 Clinical Trial

November 4 2021

PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable […]